Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Revenue of Coloplast A/S (COLO-B.CO)
Revenue in 2024 (TTM): $3.8 B
According to Coloplast A/S's latest financial reports the company's current revenue (TTM) is $3.8 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Coloplast A/S
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $3.8 B | $2.46 B | $1.2 B | $898.1 M | $709.49 M |
| 2023 | $3.44 B | $2.29 B | $1.1 B | $846.14 M | $671.72 M |
| 2022 | $3.17 B | $2.18 B | $1.02 B | $860.46 M | $660.9 M |
| 2021 | $2.73 B | $1.87 B | $994.58 M | $875.35 M | $677.61 M |
| 2020 | $2.6 B | $1.77 B | $895.99 M | $767.63 M | $589.42 M |
| 2019 | $2.52 B | $1.71 B | $805.13 M | $706.12 M | $543.92 M |
| 2018 | $2.31 B | $1.55 B | $797.27 M | $703.45 M | $539.98 M |
| 2017 | $2.18 B | $1.48 B | $787.58 M | $695.17 M | $533.24 M |
| 2016 | $2.06 B | $1.41 B | $653.32 M | $573.27 M | $441.4 M |
| 2015 | $1.95 B | $1.34 B | $247.45 M | $174.85 M | $126.25 M |
| 2014 | $1.75 B | $1.2 B | $511.76 M | $448.14 M | $335.65 M |
| 2013 | $1.63 B | $1.1 B | $584.64 M | $509.09 M | $380.73 M |
| 2012 | $1.55 B | $1.03 B | $498.13 M | $414.85 M | $308.12 M |
| 2011 | $1.43 B | $922.4 M | $435.22 M | $344.92 M | $255.46 M |
| 2010 | $1.34 B | $820.72 M | $365.42 M | $235.09 M | $174.56 M |
| 2009 | $1.24 B | $716.66 M | $269.64 M | $170.07 M | $124.01 M |
| 2008 | $1.19 B | $701.91 M | $240.71 M | $139.31 M | $100.41 M |
| 2007 | $1.13 B | $856.25 M | $187.77 M | $83.56 M | $51.96 M |
| 2006 | $942.2 M | $705.28 M | $173.72 M | $92.27 M | $65.44 M |
| 2005 | $875.21 M | $532.12 M | $188.19 M | $117.55 M | $77.66 M |
| 2004 | $852.79 M | $524.63 M | $158.85 M | $127.5 M | $82.56 M |
| 2003 | $796.14 M | $493.22 M | $208.69 M | $123.3 M | $78.79 M |
| 2002 | $789.82 M | $479.32 M | $249.14 M | $173.58 M | $107.86 M |